Ensysce Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated November 10, 2021, discloses the second closing of a Securities Purchase Agreement (SPA) entered into by Ensysce Biosciences, Inc. on September 24, 2021. The transaction involves an aggregate financing of $15 million with institutional investors. The second closing occurred on November 5, 2021, following the SEC's declaration of effectiveness for the registration statement on November 3, 2021.
Key Financial Metrics and Transaction Details
The filing details the issuance of senior secured convertible promissory notes and warrants. Specific financial terms include:
- Total Financing: $15 million aggregate.
- Second Closing (Nov 5, 2021): Issuance of Notes with a principal amount of $10.6 million for a purchase price of $10 million.
- First Closing (Sept 24, 2021): Issuance of Notes with a principal amount of $5.3 million for a purchase price of $5 million.
- Warrants Issued: 722,317 shares at the second closing and 361,158 shares at the first closing.
- Note Terms: 21-month term, 5.0% annual interest, and a 6% original issue discount.
- Conversion Price: $5.87 per share (30% premium to the average stock price prior to the first closing).
- Warrant Exercise Price: $7.63 per share (30% premium to the conversion price), exercisable for five years.
Material Changes and Obligations
The filing introduces significant debt obligations and potential equity dilution. Key changes include:
- Monthly Redemption Obligation: Commencing January 1, 2022 (for first closing notes) and February 1, 2022 (for second closing notes), the Company must redeem 92% of the average of the three lowest VWAPs in the prior ten trading days or a cash premium of 8% of 1/18th of the principal plus interest.
- Collateral: The Notes are secured by all assets of the Company and its subsidiaries, including patents.
- Guarantees: Obligations are guaranteed jointly and severally by the Company's subsidiaries.
- Unregistered Sales: The Notes and Warrants were issued under Section 4(a)(2) of the Securities Act of 1933.
Outlook, Risks, and Management Commentary
The Company has registered the resale of shares issuable upon conversion of the Notes and exercise of Warrants. The filing includes standard forward-looking statements cautioning that actual results may differ due to risks and uncertainties. The Company does not undertake a duty to update these statements except as required by law. No specific revenue guidance or operational outlook is provided in this filing, as it focuses on the financing structure.
Investor Verification Checklist
- Verify the Company's ability to meet the monthly redemption obligations starting in early 2022, which could force equity conversion or cash outflows.
- Confirm the impact of the 6% original issue discount and the 5.0% interest rate on the Company's cash burn rate.
- Assess the potential dilution from the conversion of $15.9 million in principal notes and the exercise of over 1 million warrants.
- Review the Security Agreement and Patent Security Agreement to understand the extent of assets pledged as collateral.
- Monitor the stock price relative to the $5.87 conversion price and $7.63 warrant exercise price to evaluate the likelihood of conversion or exercise.